Tetra Discovery Partners Secures $5,000,000 Series A Funding Round

  • Feed Type
  • Date
    11/30/2016
  • Company Name
    Tetra Discovery Partners
  • Mailing Address
    910 Rosewood Avenue SE Grand Rapids, MI 49506 USA
  • Company Description
    Our research focuses on developing new treatments for depression based on subtype-selective modulation of phosphodiesterase 4B (PDE4B). PDE4 in neurons is responsible for the hydrolysis of cAMP. We and our colleagues recently described the protein structure of a key PDE4 regulatory domain known as UCR2.
  • Website
    http://www.tetradiscovery.com
  • Transaction Type
    Venture Equity
  • Transaction Amount
    $5,000,000
  • Transaction Round
    Series A
  • Proceeds Purposes
    We are very pleased to receive this new financing which will enable Tetra to complete the necessary preparations for a planned Phase 2a study of our lead drug candidate, BPN14770, in Alzheimer’s disease during the second half of 2017.
  • M&A Terms
  • Venture Investor
    Apjohn Ventures
  • Venture Investor
    Grand Angels
  • Venture Investor
    Dolby Family Ventures
  • Venture Investor
    Undisclosed

Trending on Xconomy